Loading...
•
Mar 31, 2022
Amicus Therapeutics Q1 2022 Earnings Report
Amicus Therapeutics announced financial results for Q1 2022, with Galafold revenue growth and progress in regulatory reviews for AT-GAA.
Key Takeaways
Amicus Therapeutics reported Q1 2022 financial results, featuring 18.5% growth in Galafold revenue to $78.7 million. The company is advancing regulatory reviews for AT-GAA in Pompe disease and focusing on financial strength.
Galafold revenue grew by 18.5% to $78.7M in Q1 2022.
A new composition of matter patent for Galafold strengthens U.S. patent protection into 2038.
Amicus is advancing U.S. and EU regulatory reviews and launch preparations for AT-GAA in Pompe disease.
Positive long-term data from a Phase 1/2 study of AT-GAA in Pompe disease was presented at the 2022 MDA Conference.
Revenue by Segment
Forward Guidance
Amicus is focused on ensuring Galafold reaches more patients, securing regulatory approvals for AT-GAA, and maintaining the financial strength of the business.
Positive Outlook
- Continued growth of Galafold.
- Anticipated approval of AT-GAA.
- Strong exclusivity for both Galafold and AT-GAA well into the late 2030s.
- Potential for AT-GAA to become the new global standard of care in Pompe disease.
- Commitment to delivering substantial value for shareholders and patients.
Challenges Ahead
- Tumultuous market conditions.
- Potential delays in regulatory approvals.
- Risks associated with commercializing Galafold and other product candidates.
- Potential for preclinical and clinical studies to be delayed due to safety issues.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...